Healthcare review
Strong growth in Dental and Surgery driving Healthcare segment
Our Healthcare segment comprises the Dental, Drug Delivery and Surgery business units, which produce and market a broad range of products such as dispensers, cartridges, mixers, tips, syringes, pen and auto injectors for subcutaneous delivery of drugs, as well as delivery devices and mixing for bone repair and tissue treatment. These devices are used in a variety of applications by our end-customers. In the Dental business unit, our products are used for prosthetics, restoratives, anesthetics and aesthetics as well as specialties that cover endo and perio. The pen and auto injectors produced and marketed by our Drug Delivery business unit are used in fertility and growth hormone treatments, and to deliver medical substances for the treatment of diabetes, osteoporosis and other diseases. The delivery and mixing devices produced and marketed by our Surgery business unit are used by tissue banks and medical device OEMs to store, mix and/or deliver biomaterials for a variety of applications including bone repair, wound healing, hemostasis and surgical sealant applications.
Segment revenue and gross profit
January 1 – June 30
|
millions of CHF |
|
2025 |
|
+/–% change |
|
+/–% organic 2) |
|
2024 |
|
|
Dental |
|
59.9 |
|
9.1% |
|
10.1% |
|
54.9 |
|
|
Drug Delivery |
|
19.9 |
|
–6.8% |
|
–4.9% |
|
21.4 |
|
|
Surgery |
|
8.3 |
|
24.2% |
|
26.1% |
|
6.6 |
|
|
Total revenue Healthcare (HC) 1) |
|
88.1 |
|
6.2% |
|
7.5% |
|
82.9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment cost of goods sold |
|
–32.8 |
|
–4.0% |
|
|
|
–31.5 |
|
|
Segment gross profit Healthcare (HC) |
|
55.3 |
|
7.5% |
|
|
|
51.4 |
|
1) Revenue from external customers.
2) Adjusted for acquisition and currency effects.
Revenue by business unit
H1 2025
Revenue by business unit
H1 2024
Dental – continued robust growth
In the first half of 2025, the Dental business unit generated revenues of CHF 59.9 million, an organic increase of 10.1% compared with the same period last year. After strong growth in 2024, the Dental business unit continued to outgrow the market with its leading mixing and applicator solutions.
The Dental business unit has a full pipeline of innovative solutions that will be launched in the next 12 months and beyond. Our strategy to increase our presence in faster-growing product categories while maintaining the impression category as stable profit contributor mid-term is paying off.
Furthermore, a very sound operational performance contribute favorably to this excellent result.
Drug Delivery – scaling up medmix’ drug delivery platforms
The Drug Delivery business unit generated revenues of CHF 19.9 million in the first half 2025, which corresponds to an organic decrease of 4.9% compared to the same period last year. As previously communicated, this shortfall was mainly due to a customer one-off settlement that was received in H1 2024.
medmix is focusing on industrializing its two next-generation device platforms – D-Flex and PiccoJect – in close collaboration with launch customers, ramping up capacity in the Atlanta and Czech Republic production sites. First auto injectors for clinical use are being produced this year. D-Flex has been in the market with the launch customer in Europe since the end of 2023.
Surgery – double-digit organic growth in H1 2025
Revenue in our Surgery business unit grew organically by 26.1 % year-on-year to CHF 8.3 million. The increase in revenue was primarily driven by the execution of a sound order backlog and new customer product entries.
medmix has started the second phase of the ramp-up of the Atlanta site, which now produces a range of fully validated surgery products. With this new facility, medmix has increased customer proximity in the world’s largest healthcare market. This enables us to build a full portfolio of value-adding services and to become a strategic partner for customers. Furthermore, manufacturing that was previously outsourced, is being insourced to increase value creation as well as service levels.